A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. The findings provide important new insights into why patients with metastatic disease often stop responding to a key class of life-prolonging chemotherapy drugs after initially benefiting.
EIPM Researcher Selected for Prostate Cancer Foundation Challenge Award!
March 4, 2026
Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to work with researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center on an AI-based method for early detection of treatment-resistant prostate tumor subtypes.
March 2026 EIPM Directors Memo
March 4, 2026
March 2026 EIPM Director's Memo
Dear Friends & Members of the Englander Institute,
EIPM Clinical Director recognized as one of the 2025 Best Female Scientists in the World!
February 9, 2026
Please join us in congratulating our Clinical Director Dr. Cora N.
February 2026 EIPM Director's Memo
February 9, 2026
Dear Friends & Members of the Englander Institute,
New Laboratory to Advance Personalized, Cell-Based Cancer Therapies
February 5, 2026
Dr. George Coukos, an internationally renowned expert on cancer immunology, is on a mission to rapidly translate tumor biology research into personalized, cell-based therapies for patients with some of the hardest-to-treat cancers. A new laboratory, part of an innovative collaboration between Weill Cornell Medicine and the Ludwig Institute for Cancer Research, seeks to do just that.
Renowned Cell Therapy Expert Joins the EIPM!
February 4, 2026
Dr. George Coukos, a physician-scientist and international authority on tumor immunology and cellular immunotherapy, is joining Weill Cornell Medicine on Feb. 1 to lead the new Ludwig Laboratory for Cell Therapy. He previously was founding director of the Ludwig Lausanne Branch in Switzerland.
December 2025 EIPM Town Hall Highlights
January 19, 2026
“Vision, Growth, and Priorities.”
Highlights from the December 18th Town Hall by EIPM Director Olivier Elemento, Ph.D.
The Englander Institute for Precision Medicine gathered faculty, staff, and trainees for our annual Town Hall meeting on December 18th led by Director Olivier Elemento, Ph.D., who used the occasion to focus on the EIPM’s future direction, ongoing initiatives, and strategic priorities, highlighting both significant accomplishments and the challenges ahead.
Mission Remains Steady Amid Change
Whole-Genome Sequencing May Optimize PARP Inhibitor Use
January 12, 2026
A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest further development of this approach is merited.
EIPM's Fourth Quarter External Newsletter
January 6, 2026
Dear Friends & Members of the Englander Institute,
Welcome to fourth quarterly external newsletter of 2025!